Enliven Therapeutics Prices $400M Upsized Offering of 8.9M Shares at $37.50
ELVN•Enliven Therapeutics priced an upsized public offering of 8,933,334 common shares at $37.50 and pre-funded warrants for 1,733,333 shares at $37.499, targeting gross proceeds of about $400 million before fees. Underwriters hold a 30-day option to purchase up to 1.6 million additional shares at the same public offering price.
1. Offering Structure and Pricing
Enliven Therapeutics launched an upsized underwritten offering comprising 8,933,334 common shares at $37.50 each and pre-funded warrants allowing holders to acquire up to 1,733,333 additional shares at $37.499 apiece, with a nominal $0.001 exercise price per warrant.
2. Proceeds and Closing Timeline
The offering is expected to generate approximately $400.0 million in gross proceeds before underwriting discounts, commissions and offering expenses, and is scheduled to close on or about June 15, 2026, subject to customary closing conditions.
3. Underwriter Option and Syndicate
Underwriters have a 30-day option to purchase up to 1,600,000 additional common shares at the public offering price less discounts and commissions. Jefferies, Goldman Sachs, Morgan Stanley and Barclays serve as joint book-running managers, with Mizuho and LifeSci Capital in supporting roles and Baird and Jones also participating in the syndicate.
